ENTADFI Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Entadfi, and when can generic versions of Entadfi launch?
Entadfi is a drug marketed by Blue Water Biotech and is included in one NDA.
The generic ingredient in ENTADFI is finasteride; tadalafil. There are fourteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the finasteride; tadalafil profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Entadfi
A generic version of ENTADFI was approved as finasteride; tadalafil by ZYDUS on March 15th, 2024.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ENTADFI?
- What are the global sales for ENTADFI?
- What is Average Wholesale Price for ENTADFI?
Summary for ENTADFI
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ENTADFI |
What excipients (inactive ingredients) are in ENTADFI? | ENTADFI excipients list |
DailyMed Link: | ENTADFI at DailyMed |
Pharmacology for ENTADFI
Drug Class | 5-alpha Reductase Inhibitor Phosphodiesterase 5 Inhibitor |
Mechanism of Action | 5-alpha Reductase Inhibitors Phosphodiesterase 5 Inhibitors |
US Patents and Regulatory Information for ENTADFI
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Blue Water Biotech | ENTADFI | finasteride; tadalafil | CAPSULE;ORAL | 215423-001 | Dec 9, 2021 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |